Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Queensland Health
Accenture
Cipla
Boehringer Ingelheim
Federal Trade Commission

Generated: July 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,320,712

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,320,712 protect, and when does it expire?

Patent 9,320,712 protects PRECEDEX and is included in one NDA.

Protection for PRECEDEX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-five patent family members in thirty-two countries.

Summary for Patent: 9,320,712
Title:Dexmedetomidine premix formulation
Abstract: The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.
Inventor(s): Roychowdhury; Priyanka (Foster City, CA), Cedergren; Robert A. (Libertyville, IL)
Assignee: HOSPIRA, INC. (Lake Forest, IL)
Application Number:14/177,008
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,320,712
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 9,320,712
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Drugs Protected by US Patent 9,320,712

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Hospira PRECEDEX dexmedetomidine hydrochloride INJECTABLE;INJECTION 021038-004 Nov 14, 2014 AP RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Hospira PRECEDEX dexmedetomidine hydrochloride INJECTABLE;INJECTION 021038-002 Mar 13, 2013 AP RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Hospira PRECEDEX dexmedetomidine hydrochloride INJECTABLE;INJECTION 021038-003 Mar 13, 2013 AP RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 9,320,712

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 089673 ➤ Sign Up
Australia 2013201069 ➤ Sign Up
Brazil 112013008005 ➤ Sign Up
Canada 2806706 ➤ Sign Up
Chile 2013000815 ➤ Sign Up
China 103281902 ➤ Sign Up
China 107802624 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Moodys
Express Scripts
Medtronic
Colorcon
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.